SCHEMBL215720

SCHEMBL215720

CC(C)(C)OC(=O)N1CCCC(OS(C)(=O)=O)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.49
ALDH1A1 P00352 1/20 0.49
MAPT P10636 1/20 0.49
KMT2A Q03164 1/20 0.49
HPGD P15428 1/20 0.47
PRMT5 O14744 1/20 0.43
WDR77 Q9BQA1 1/20 0.43
EPHX1 P07099 1/20 0.42
SCN9A Q15858 1/20 0.41
PDE4B Q07343 1/20 0.41
GPR119 Q8TDV5 3/20 0.41
USP30 Q70CQ3 2/20 0.40
PREP P48147 1/20 0.40
CHEK2 O96017 1/20 0.40
USP2 O75604 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MMP1 P03956 1/20 0.39
MMP9 P14780 1/20 0.39
MMP13 P45452 1/20 0.39
JAK2 O60674 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL215721 1.00 MEN1 (0.49) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL731800 1.00 MEN1 (0.49) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL9938442 0.96 HPGD (0.49) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL31045719 0.94 HPGD (0.51) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL66145 0.91 GPR119 (0.48) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL330785 0.91 GPR119 (0.48) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL66134 0.91 GPR119 (0.48) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL4008565 0.89 HPGD (0.54) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL29981135 0.89 HPGD (0.54) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL5538557 0.86 GPR119 (0.45) MEN1ALDH1A1MAPTKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 434 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747250-A1 KINASE INHIBITORS The United States Of America, As Represented By The Secretary, Department of Health and Human Services (US) 2026-05-27 EP disclosed
US-12624044-B2 SMARCA degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-05-12 US disclosed
US-12544382-B2 2, 4, 6-tri-substituted pyrimidine compound as ATR kinase inhibitor BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) 2026-02-10 US disclosed
EP-4288426-B1 QUINOXALINE DERIVATIVES AND USES THEREOF BLACK DIAMOND THERAPEUTICS INC (US) 2026-02-04 EP disclosed
EP-4665733-A1 AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 Bristol-Myers Squibb Company (US) 2025-12-24 EP disclosed
EP-3867248-B1 PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS NXERA PHARMA UK LTD (GB) 2025-12-10 EP disclosed
EP-4648763-A2 COMPOUNDS FOR FGFRS INHIBITORS Cogent Biosciences, Inc. (US) 2025-11-19 EP disclosed
US-20250332173-A1 COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING REMIX THERAPEUTICS INC (US) 2025-10-30 US disclosed
EP-4618755-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN Larkspur Biosciences, Inc. (US) 2025-09-24 EP disclosed
EP-3590516-B1 ANTITUMOR-EFFECT ENHANCER USING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND TAIHO PHARMACEUTICAL CO LTD (JP) 2025-09-03 EP disclosed
EP-0969840-A4 THROMBIN INHIBITORS MERCK & CO INC (US) 2001-02-28 EP disclosed
EP-0969840-A1 THROMBIN INHIBITORS Merck & Co., Inc. (US) 2000-01-12 EP disclosed
US-5932606-A Pyrazinone, pyridinone, piperidine and pyrrolidine thrombin inhibitors MERCK & CO., INC. (US) 1999-08-03 US disclosed
US-5856318-A Nitrogen-containing cyclohetero cyclo-heteroaminoaryl derivatives for CNS disorders THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1999-01-05 US disclosed
WO-1998042342-A1 THROMBIN INHIBITORS MERCK & CO., INC. (US) 1998-10-01 WO disclosed
US-5656625-A ANTIISCHEMIC AGENT, PSYCHOLOGICAL DISORDER, ANTICONVULSANT THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1997-08-12 US disclosed
US-5571832-A Nitrogen-containing cyclohetero alkylamino aryl derivatives for CNS disorders THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1996-11-05 US disclosed
US-5346908-A Anticonvulsant NATIONAL INSTITUTES OF HEALTH (US) 1994-09-13 US disclosed
US-5342846-A 7-substituted-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid compounds and 7-(substituted triazolyl pyrrolidin-1-yl) 4-oxoquinoline-3-carboxylic acid derivatives useful as antibacterial agents SYNPHAR LABORATORIES, INC. (CA) 1994-08-30 US disclosed
WO-1993024481-A1 7-SUBSTITUTED-6-FLUORO-1,4-DIHYDRO-4-OXO-QUINOLINE-3-CARBOXYLIC ACID COMPOUNDS AND RELATED COMPOUNDS AS ANTIBACTERIAL AGENTS SYNPHAR LABORATORIES, INC. (CA) 1993-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250332173-A1 COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING SNRPA, NSUN2, SNRPA1 MEN1 3613/4885ALDH1A1 3447/4885MAPT 3442/4885
US-12624044-B2 SMARCA degraders and uses thereof SMARCA1, SMARCC1, SMARCA2 MEN1 1936/4885ALDH1A1 3543/4885MAPT 2169/4885
US-12544382-B2 2, 4, 6-tri-substituted pyrimidine compound as ATR kinase inhibitor ATR, CHEK1, CHEK2 MEN1 3566/4885ALDH1A1 3420/4885MAPT 3379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.